Am J Perinatol 2005; 22(3): 169-172
DOI: 10.1055/s-2005-864855
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Breakthrough Candida Infection in a Preterm Infant with Congenital Cutaneous Candida albicans Infection

Amos Adler1 , Ita Litmanovitz1 , Rivka Regev1 , Shmuel Arnon1 , Sophia Bauer1 , Tzipora Dolfin1
  • 1Department of Neonatology, Meir Medical Center, Kfar-Saba; affiliated to the Tel-Aviv University-Sackler School of Medicine, Israel
Further Information

Publication History

Publication Date:
11 April 2005 (online)

Preview

ABSTRACT

Amphotericin B is the primary antifungal agent used for candida sepsis in neonates. Breakthrough candidemia was not reported in neonates during either amphotericin B or liposomal amphotericin B (AmBisome) treatment. We describe a case of a premature infant with congenital cutaneous candida infection, who had two episodes of breakthrough infection, from Candida albicans and Candida parapsilosis, while he was treated with amphotericin B and AmBisome, respectively. We discuss the pathogenesis of breakthrough infections, and the relevance of antifungal resistance and sensitivities testing.

REFERENCES

Amos AdlerM.D. 

Department of Neonatology, Meir Medical Center

59 Tsharnichovsky Street, Kfar-Saba 95847, Israel